Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 4, 2019 22:34 UTC |
Wellisch Alejandro DSenior Vice President
|
GrantCommon shares without par value | 6,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003127 · edgar.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,032 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:35 UTC |
WHITE MILES DDirector · Chairman and CEO
|
Tax withholdingCommon shares without par value | 52,302 | $77.23 | $4,039,283.46 |
DisclosureSEC source: 0001179110-19-003128 · edgar.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,174,165 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:35 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Tax withholdingCommon shares without par value | 13,127 | $77.23 | $1,013,798.21 |
DisclosureSEC source: 0001179110-19-003129 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,627 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:02 UTC |
ALLEN HUBERT LExecutive Vice President
|
GrantOption (right to buy) · Derivative | 151,933 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002630 · edgar.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,933 Underlying: Common shares · 151,933 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 50,644 on February 22, 2020, 50,644 on February 22, 2021, and 50,645 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:02 UTC |
ALLEN HUBERT LExecutive Vice President
|
GrantCommon shares without par value | 28,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002630 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,099 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:03 UTC |
BIRD ROGERSenior Vice President
|
GrantOption (right to buy) · Derivative | 99,706 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002631 · edgar.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,706 Underlying: Common shares · 99,706 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 33,235 on February 22, 2020, 33,235 on February 22, 2021, and 33,236 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:03 UTC |
BIRD ROGERSenior Vice President
|
GrantCommon shares without par value | 19,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002631 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,195 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:04 UTC |
Blaser Brian J.Executive Vice President
|
GrantOption (right to buy) · Derivative | 148,895 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002633 · edgar.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,895 Underlying: Common shares · 148,895 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 49,631 on February 22, 2020, 49,632 on February 22, 2021, and 49,632 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:04 UTC |
Blaser Brian J.Executive Vice President
|
GrantCommon shares without par value | 28,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002633 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,563 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:05 UTC |
Bracken Sharon JSenior Vice President
|
GrantOption (right to buy) · Derivative | 90,642 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002636 · edgar.xml · derivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,642 Underlying: Common shares · 90,642 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,214 on February 22, 2020, 30,214 on February 22, 2021, and 30,214 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:05 UTC |
Bracken Sharon JSenior Vice President
|
GrantCommon shares without par value | 17,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002636 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,321 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:05 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantOption (right to buy) · Derivative | 81,578 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002637 · edgar.xml · derivative · entry 2 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,578 Underlying: Common shares · 81,578 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:05 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantCommon shares without par value | 15,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002637 · edgar.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,422 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:06 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 101,519 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002638 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,519 Underlying: Common shares · 101,519 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 33,839 on February 22, 2020, 33,840 on February 22, 2021, and 33,840 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:06 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantCommon shares without par value | 19,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002638 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,667 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:06 UTC |
Contreras JaimeSenior Vice President
|
GrantOption (right to buy) · Derivative | 77,045 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002639 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,045 Underlying: Common shares · 77,045 shares Expires 2029-02-21 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,681 on February 22, 2020, 25,682 on February 22, 2021, and 25,682 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:06 UTC |
Contreras JaimeSenior Vice President
|
GrantCommon shares without par value | 14,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002639 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,999 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC |
Ford Robert BPresident and COO
|
GrantOption (right to buy) · Derivative | 240,059 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002640 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,059 Underlying: Common shares · 240,059 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 80,019 on February 22, 2020, 80,020 on February 22, 2021, and 80,020 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC |
Ford Robert BPresident and COO
|
GrantCommon shares without par value | 45,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002640 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,572 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC |
Funck, Jr. Robert E.Senior Vice President
|
GrantOption (right to buy) · Derivative | 122,367 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002641 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,367 Underlying: Common shares · 122,367 shares Expires 2029-02-21 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 40,789 on February 22, 2020, 40,789 on February 22, 2021, and 40,789 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC |
Funck, Jr. Robert E.Senior Vice President
|
GrantCommon shares without par value | 23,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002641 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,673 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC |
Fussell Stephen RExecutive Vice President
|
GrantOption (right to buy) · Derivative | 138,121 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002642 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,121 Underlying: Common shares · 138,121 shares Expires 2029-02-21 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 46,040 on February 22, 2020, 46,040 on February 22, 2021, and 46,041 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC |
Fussell Stephen RExecutive Vice President
|
GrantCommon shares without par value | 26,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002642 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,402 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
Karam SammySenior Vice President
|
GrantOption (right to buy) · Derivative | 81,578 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002643 · edgar.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,578 Underlying: Common shares · 81,578 shares Expires 2029-02-21 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:10 UTC |
LANE ANDREW HExecutive Vice President
|
GrantOption (right to buy) · Derivative | 115,055 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002644 · edgar.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,055 Underlying: Common shares · 115,055 shares Expires 2029-02-21 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,351 on February 22, 2020, 38,352 on February 22, 2021, and 38,352 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:10 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantOption (right to buy) · Derivative | 81,578 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002645 · edgar.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,578 Underlying: Common shares · 81,578 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:10 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantCommon shares without par value | 15,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002645 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,036 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:11 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantOption (right to buy) · Derivative | 72,513 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002646 · edgar.xml · derivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,513 Underlying: Common shares · 72,513 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,171 on February 22, 2020, 24,171 on February 22, 2021, and 24,171 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:11 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantCommon shares without par value | 13,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002646 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,751 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
GrantOption (right to buy) · Derivative | 162,430 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002647 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,430 Underlying: Common shares · 162,430 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 54,143 on February 22, 2020, 54,143 on February 22, 2021, and 54,144 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
GrantCommon shares without par value | 30,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002647 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,509 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC |
Watkin JaredSenior Vice President
|
GrantOption (right to buy) · Derivative | 108,770 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002648 · edgar.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,770 Underlying: Common shares · 108,770 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,256 on February 22, 2020, 36,257 on February 22, 2021, and 36,257 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC |
Watkin JaredSenior Vice President
|
GrantCommon shares without par value | 20,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002648 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,390 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:13 UTC |
Wellisch Alejandro DSenior Vice President
|
GrantOption (right to buy) · Derivative | 81,578 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002649 · edgar.xml · derivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,578 Underlying: Common shares · 81,578 shares Expires 2029-02-21 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:14 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantOption (right to buy) · Derivative | 522,272 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002650 · edgar.xml · derivative · entry 3 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,272 Underlying: Common shares · 522,272 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 174,090 on February 22, 2020, 174,091 on February 22, 2021, and 174,091 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:14 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantCommon shares without par value | 99,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002650 · edgar.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,226,467 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:15 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
GrantOption (right to buy) · Derivative | 169,198 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002651 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,198 Underlying: Common shares · 169,198 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 56,399 on February 22, 2020, 56,399 on February 22, 2021, and 56,400 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:15 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
GrantCommon shares without par value | 32,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002651 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,754 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 22:07 UTC |
Karam SammySenior Vice President
|
Tax withholdingCommon shares without par value | 792 | $75.25 | $59,598.00 |
DisclosureSEC source: 0001179110-19-002152 · edgar.xml · nonDerivative · entry 3 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,290 Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 22:09 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Tax withholdingCommon shares without par value | 505 | $75.25 | $38,001.25 |
DisclosureSEC source: 0001179110-19-002155 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,918 Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 22:08 UTC |
Wellisch Alejandro DSenior Vice President
|
Tax withholdingCommon shares without par value | 710 | $75.25 | $53,427.50 |
DisclosureSEC source: 0001179110-19-002153 · edgar.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,356 Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 22:07 UTC |
Karam SammySenior Vice President
|
Tax withholdingCommon shares without par value | 771 | $75.25 | $58,017.75 |
DisclosureSEC source: 0001179110-19-002152 · edgar.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,082 Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 22:09 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Tax withholdingCommon shares without par value | 450 | $75.25 | $33,862.50 |
DisclosureSEC source: 0001179110-19-002155 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,423 Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 22:07 UTC |
Karam SammySenior Vice President
|
Tax withholdingCommon shares without par value | 814 | $75.25 | $61,253.50 |
DisclosureSEC source: 0001179110-19-002152 · edgar.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,853 F1 · balance_after: Includes shares acquired under the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 22:43 UTC |
Stratton John GDirector
|
PurchaseCommon shares without par value | 100 | $72.32 | $7,231.50 |
DisclosureSEC source: 0001179110-19-001172 · edgar.xml · nonDerivative · entry 5 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 22:43 UTC |
Stratton John GDirector
|
PurchaseCommon shares without par value | 100 | $72.31 | $7,230.50 |
DisclosureSEC source: 0001179110-19-001172 · edgar.xml · nonDerivative · entry 4 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 22:43 UTC |
Stratton John GDirector
|
PurchaseCommon shares without par value | 1,800 | $72.33 | $130,194.00 |
DisclosureSEC source: 0001179110-19-001172 · edgar.xml · nonDerivative · entry 3 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 22:43 UTC |
Stratton John GDirector
|
PurchaseCommon shares without par value | 842 | $72.32 | $60,893.44 |
DisclosureSEC source: 0001179110-19-001172 · edgar.xml · nonDerivative · entry 2 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 22:43 UTC |
Stratton John GDirector
|
PurchaseCommon shares without par value | 613 | $72.31 | $44,326.03 |
DisclosureSEC source: 0001179110-19-001172 · edgar.xml · nonDerivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,558 Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 22:44 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 77,550 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-001173 · edgar.xml · derivative · entry 16 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,860 Underlying: Common Shares · 77,550 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.